CVS Health Raises FY2025 Adj EPS Guidance from $6.55-$6.65 to $6.60-$6.70 vs $6.38 Est; Raises FY2025 Sales Guidance from At Least $397.3B to $400B vs $394.594B Est

2025 full-year financial guidance

Today, the Company is updating its 2025 full-year financial guidance provided on its October 29, 2025 earnings call as follows:

• Raised total revenues guidance to at least $400.0 billion from at least $397.3 billion
• Raised GAAP operating income guidance range to $4.37 billion to $4.54 billion from $4.29 billion to $4.46 billion
• Raised adjusted operating income guidance range to $14.22 billion to $14.39 billion from $14.14 billion to $14.31 billion
• Raised GAAP diluted earnings (loss) per share guidance range to $(0.32) to $(0.22) from $(0.34) to $(0.24)
• Raised Adjusted EPS guidance range to $6.60 to $6.70 from $6.55 to $6.65
• Confirmed cash flow from operations guidance range of $7.5 billion to $8.0 billion